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Abstract Using the recently developed methodology of nucleic
acid microarrays spotted with specific cDNAs probes belonging
to different gene families, we showed for the first time that
nanomolar concentrations of the cannabinoid ligand CP-55940
upregulated the expression of two different members of the
chemokine gene family: the K-chemokine interleukin-8 (IL-8)
and the L-chemokine monocyte chemotactic protein-1 (MCP-1),
in the promyelocytic cell line HL60 transfected with peripheral
cannabinoid receptors (CB2). These genomic modulations
observed on large-scale cDNA arrays were first confirmed by
Northern blot studies. Furthermore, ELISA evaluations in
culture supernatants indicated that the cannabinoid-induced
activation of these two chemokine genes was followed by
enhanced expression and secretion of the corresponding proteins.
These upregulations initially observed in transfected HL60 cells
overexpressing CB2 receptors, also occurred in normal non-
transfected HL60 cells. The enhancement of IL-8 and MCP-1
gene transcription and protein production was shown to be
pertussis toxin sensitive attesting that this phenomenon was a Gi
protein-coupled receptor-mediated process as expected for
cannabinoid receptors. More specifically, the abolition of the
cannabinoid-induced effect by the specific CB2 antagonist SR
144528 indicated a strict peripheral cannabinoid-mediated
process. Altogether, our data highlight a possible new function
of peripheral cannabinoid receptors in the modulation of immune
and inflammatory responses.
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1. Introduction
Cannabinoid receptors belong to the G protein-coupled re-
ceptor (GPCR) super family. To date, two receptor types have
been identi¢ed and are referred to as CB1 and CB2 [1^3]. CB1
receptors are expressed in the central nervous system and
some peripheral tissues whereas CB2 is only present at the
periphery and especially on cells of immune origin [4^6].
However, despite the characterization and the localization of
these receptors on immune cells [5,6], the identi¢cation of
second messenger systems [7], the ¢nding of putative endoge-
nous ligands [8,9] and the availability of synthetic agonists
and speci¢c antagonist ligands [10,11], the function of canna-
binoid receptors in the immune system still remains an enig-
ma. So far, with the exception of few examples [12^14], most
of the studies showed immunosuppressive e¡ects of cannabi-
noids in very di¡erent areas of immunity, for instance inhi-
bition of lymphocyte proliferative response [15,16], antibody
production [17], cytotoxic activity or cytokine production [18].
These widespread suppressive e¡ects interfering with many
di¡erent functions were observed in most cases at cannabinoid
ligand concentrations much higher (s 1 WM) than those re-
quired for binding to the receptor and raised the question of
the relevance of the observed e¡ects in terms of the receptor
speci¢city.
In an attempt to elucidate the role of CB2 receptors in the
immune system we used an original approach. Our analysis
was carried out using a cell line overexpressing CB2: in this
system, we compared the patterns of gene expression before
and after the stimulation of cells with physiological concen-
trations of cannabinoid ligands, using large-scale cDNAs mi-
croarrays spotted with hundreds of cDNAs probes grouped
into di¡erent gene families involved in di¡erent biological
processes. We then investigated whether the proteins under
the control of the modulated genes similarly varied in both
transfected and wild-type cells, and ¢nally we made sure that
the observed events were mediated via CB2 receptors by the
use of speci¢c antagonist ligands.
2. Materials and methods
2.1. Reagents
CP-55940 was obtained from P¢zer. SR 144528 (N-((1S)-endo-
1,3,3-trimethylbicyclo(2,2,1)heptan-2-yl)-5-(4-chloro-3-methylphenyl)-
1-(4-methylbenzyl)-pyrazole-3-carboxamide) and SR 141716A (N-(pi-
peridin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-
pyrazole-3-carboxamide hydrochloride) were synthesized at the chem-
istry department, Sano¢ Recherche (Montpellier, France). Pertussis
toxin (PTX) was purchased from Sigma chemicals.
2.2. Cell culture and treatment
Cell lines were grown at 37‡C in humidi¢ed 5% CO2 in RPMI 1640
medium (Gibco-BRL, Gaithersburg, MD, USA) supplemented with
10% heat-inactivated fetal calf serum (FCS), 25 mM HEPES, 2.5 mM
sodium pyruvate and 20 Wg/ml gentamicin. The human promyelocytic
cell line HL60 was purchased from ATCC (American tissue culture
collection). Stable transfection of the HL60 cell line with CB2 (HL60-
CB2) was performed as follows: cells were transfected with the re-
combinant plasmid pCDNA3-CB2 by electroporation and then main-
tained in the presence of 600 Wg/ml Geneticin. Cells were screened
4 weeks later for CB2 receptor expression by £ow cytometry using
an anti-CB2 receptor polyclonal antibody [19]. For RNA extraction,
cells were grown in a culture medium with 0.5% FCS 24 h prior
treatment with 10 nM CP-55940 or 200 nM SR 144528 for di¡erent
time periods.
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2.3. RNA isolation and northern blot analysis
Total RNA was isolated from cells by lysis in guanidinium isothio-
cyanate and puri¢ed by cesium chloride gradient ultracentrifugation.
The integrity of RNAs was assessed by analysing 18S and 28S ribo-
somal RNA. Poly(A) RNA was then extracted with a fast track
mRNA isolation Kit (Invitrogen NV, Leek, The Netherlands). For
Northern blot analysis, 1 Wg poly(A) RNA or 20 Wg total RNA per
lane was electrophoresed in 1% agarose-formaldehyde gels. RNA was
transferred to Nytran (Schleicher and Schuell, France), cross-linked
and hybridized to 32P-labeled cDNA in a Church bu¡er [20]. The
human MCP-1 and IL-8 radiolabeled probes were prepared from
PCR products obtained with the following primers: 5P-TCCAGCAT-
GAAAGTCTCTGC-3P and 5P-TGGAATCCTGAACCCACTTC-3P
(human MCP-1) or 5P-TTGGCAGCCTTCCTGATTTC-3P and 5P-
AACTTCTCCACAACCCTCTG-3P (human IL-8).
2.4. 32P-Labeled cDNAs synthesis and Atlas human cDNA expression
array I hybridization
The Atlas human cDNA expression array I was purchased from
Clontech (Palo Alto, CA). 32P-Labeled cDNA probes were performed
using 1 Wg poly(A) RNA from HL60-CB2 cells (control) or HL60-
CB2 treated with 10 nM CP-55940 for 1 h. Brie£y, poly(A) were
reverse-transcribed using gene-speci¢c primers and MMLV reverse
transcriptase in the presence of [K-32P]dATP. Complex [32P]cDNA
from each sample was puri¢ed on a chroma-spin column and counted.
About 3U106 cpm from each probe were hybridized to a separate
Atlas human cDNA array membrane in Church bu¡er at 68‡C over-
night. After a high-stringency wash, blots were exposed to Amersham
Hyper¢lm MP with an intensifying screen.
2.5. Measurements of chemokine production
CB2-transfected and wt HL60 cells were incubated at 37‡C in a 5%
CO2 atmosphere at 106 cells/ml with the indicated concentrations of
CP-55940 in RPMI medium supplemented with 0.5% FCS. After a 24
h incubation culture supernatants were collected and levels of IL-8,
MCP-1, MIP-1K or GRO-K were determined using ELISA kits from
RpD Systems (Abingdon, UK). In some experiments, cells were
treated overnight with 100 ng/ml PTX and extensively washed before
exposure to CP-55940. When needed the CB1 and CB2 receptor an-
tagonists SR 141716 and SR 144528, respectively, were added to the
cells 30 min before the addition of CP-55940. The data shown are
means of duplicate wells and experiments were done at least twice. In
some experiments results were expressed as % increase in chemokine
production as follows:




3.1. Induction of MCP-1 and IL-8 genes expression through
CB2 receptor
We have previously demonstrated by RT-PCR that the hu-
man promyelocytic cell line (HL60) expresses mRNAs for the
peripheral cannabinoid receptor CB2 whereas mRNAs for the
central cannabinoid receptor CB1 are undetectable [6], mak-
ing these cells very suitable to monitor the gene expression
pro¢le associated with a stimulation of the peripheral canna-
binoid receptor. In order to amplify the genomic changes
associated with a functional coupling of the peripheral recep-
tor, transfected HL60 cells stably overexpressing the CB2 re-
ceptor (HL60-CB2) were used in a ¢rst approach.
The gene expression pro¢le of HL60-CB2 cells, stimulated
for 1 h with 10 nM CP-55940, was thus compared with that of
their non-stimulated counterparts. The hybridization of their
respective poly(A) RNAs to separated Atlas human cDNA
expression membranes made it possible to simultaneously as-
sess in one single hybridization the expression of 588 cDNAs
reported to play key roles in many di¡erent biological proc-
esses. The patterns shown in Fig. 1 clearly reveal for the ¢rst
time that stimulation of the CB2 receptors led to an increased
expression of two chemokine genes: MCP-1 and IL-8.
To con¢rm that changes in hybridization signals corre-
sponded to real changes in mRNA abundance between the
two samples, Northern blots were performed using speci¢c
MCP-1 and IL-8 probes. As shown in Fig. 2A, incubation
of HL60-CB2 with the CB agonist for 1 h induced a signi¢-
cant increase in both MCP-1 and IL-8 mRNA levels. These
inductions were not artefactually restricted to CB2 overex-
pressing cells but were also observed at a lower level in nor-
mal non-transfected cells and especially in MCP-1 mRNAs.
Kinetic studies (Fig. 2B) showed a di¡erential time-dependent
increase in MCP-1 and IL-8 mRNAs. Whereas MCP-1
mRNA expression reached a peak after 1 h of treatment
with the CB agonist, 3 h were required for a maximum IL-8
mRNA expression. In both cases however, the levels of tran-
scripts similarly declined after a 6 h treatment.
The receptor-speci¢city of MCP-1 and IL-8 mRNAs upre-
gulation was evaluated at the respective optimal time with the
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Fig. 1. Di¡erential gene expression in control and CP-55940 treated human promyelomonocytic cell line HL60 stably transfected with CB2.
Poly(A) RNA was isolated from the indicated samples. 32P-labeled cDNA probes were generated from each poly(A) sample and hybridized
to separate Atlas human cDNA arrays I membranes as described in Section 2. Autoradiography was performed overnight with an intensifying
screen.
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CB2 speci¢c antagonist SR 144528 tested at 200 nM alone or
in combination with 10 nM CP-55940. Fig. 2B shows that the
CP-induced e¡ects on MCP-1 and IL-8 mRNAs were com-
pletely blocked by SR 144528, clearly indicating a CB2 recep-
tor-mediated process. The decrease in the basal level of both
mRNA populations when cells were treated with SR 144528
alone con¢rmed the inverse agonist pro¢le of this compound
[21].
3.2. E¡ect of CP-55940 on MCP-1 and IL-8 protein production
To test whether the upregulation of MCP-1 and IL-8 gene
transcription was followed by the production of the corre-
sponding proteins, we evaluated the levels of these chemo-
kines in the culture supernatants of HL60 cells stimulated
for 24 h with the cannabinoid agonist CP-55940. First, the
range of increase in IL-8 and MCP-1 protein level in wild-type
HL60 was compared with that in CB2-transfected HL60 after
stimulation with 100 nM CP. In both cell subtypes CP in-
creased IL-8 production by 52 and 70% respectively whereas
in the same conditions MCP-1 production was enhanced by
80 and 42%, respectively (Fig. 3). The two proteins being very
signi¢cantly upregulated in CB2 transfected and normal HL60
cells as well, these latter were used in most of the following
experiments unless otherwise stated.
Since cannabinoid receptors are linked to Gi protein, in a
¢rst approach to demonstrate the receptor speci¢city in this
phenomenon, we evaluated the e¡ect of the Go-Gi protein
inhibitor PTX on the CP-induced increase in these two che-
mokines expression level. As shown in Fig. 4a,b, PTX totally
abolished the stimulating activity of the cannabinoid ligand
on IL-8 and MCP-1 production whatever the CP-55940 con-
centrations tested, clearly indicating a Go-Gi protein-coupled
receptor-mediated process. In the absence of PTX, the EC50
of CP-55940 for both IL-8 and MCP-1 enhancements were
evaluated at about 2 nM. This low nanomolar concentration
was in line with the a⁄nity of this ligand for the cannabinoid
receptors [22], strengthening the notion of a cannabinoid re-
ceptor-induced e¡ect.
However, CP-55940 displays high but equivalent a⁄nity for
both CB1 and CB2 receptors. Therefore, to ascertain that the
CB2 was the receptor subtype involved in the observed e¡ects,
as for the studies on gene expression pro¢le, the CB2 antag-
onist SR 144528 [11] was used in combination with the ago-
nist. Fig. 4c,d shows that the stimulating e¡ect induced by 30
nM CP-55940 on IL-8 and MCP-1 was abolished by the spe-
ci¢c CB2 antagonist. A complete inhibition was observed at
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Fig. 3. E¡ect of CP-55940 on MCP-1 and IL-8 protein production.
The levels of MCP-1 and IL-8 proteins were evaluated by ELISA in
the culture supernatants of wt (a and b) or CB2 (c and d) HL60
cells stimulated for 24 h with 100 nM CP-55940.
Fig. 2. MCP-1 and Il-8 are speci¢cally inducible in HL60-CB2 cells by the cannabinoid agonist CP-55940. Total RNA was isolated from ap-
proximately 2U107 cells. Northern blots were performed using 20 Wg of total RNA per lane. Filters were sequentially hybridized to the
[32P]cDNA probes MCP-1 and IL-8. Ethidium bromide-stained gels indicate the integrity and the relative amount of RNA loaded in individual
lanes. A: E¡ect of CP-55940 in upregulating MCP-1 and IL-8 mRNA expression in HL60-CB2 and HL60 wild type. Cells were maintained in
culture medium containing 0.5% fetal calf serum for 24 h and then incubated for 1 h at 37‡C with (lanes 2 and 4) or without (lanes 1 and 3)
10 nM of CP-55940. B: Time course of CP-55940 on MCP-1 and IL-8 mRNA expression in HL60-CB2 cells, and e¡ect of the CB2 antagonist
SR 144528. Cells were incubated with or without 10 nM CP-55940 for up to 6 h. For SR 144528 e¡ects, HL60-CB2 cells were treated with
200 nM of SR 144528 alone or in association with 10 nM CP-55940 for 3 h.
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200 nM antagonist with an IC50 around 30 nM in both cases.
A similar result was obtained in CB2-transfected HL60 cells
where, in addition to the CB2 antagonist, the CB1 antagonist
SR141716 [10] was also tested and shown to be unable to
block the stimulating e¡ect of CP-55940 on MCP-1 produc-
tion (Fig. 4e). These data con¢rmed a speci¢c CB2-receptor-
mediated e¡ect as already observed at the transcriptional lev-
els. In contrast to what was clearly observed with the potent
synthetic ligand CP-55940, neither the putative endogenous
ligand anandamide, nor the psychoactive component of mar-
ijuana v9-THC were able to modulate the production of these
two chemokines (not shown).
Finally, we tested the e¡ect of CP-55940 on two other che-
mokines, GRO-K which belongs to the same K-chemokine
family as IL-8 and MIP-1K, a L-chemokine family member
as MCP-1. The experiment depicted in Fig. 5 shows that un-
like IL-8 or MCP-1, neither GRO-K nor MIP-1K production
was a¡ected by the CP-55940 treatment.
4. Discussion
With regard to the impact on the immune system, canna-
binoids have been mainly shown to impair immunological
functions in vitro and in vivo, including de¢ciency of lympho-
cyte blastogenesis, suppression of antibody formation, de¢-
ciency of cytokines production, etc. [23]. However, these re-
ports have little meaning since most of them were observed
using drug concentrations outside the physiological range and
probably via receptor-independent pathways. An additional
intricacy is the fact that the two receptor subtypes so far
characterized are often coexpressed in the same cells, leading
to a di⁄cult interpretation of the respective commitment of
both receptors in the immune system. Therefore, the exact
function of the CB receptor in the immune system is still
poorly understood although some work has clearly suggested
that the CB2 receptor seems to be involved in the cannabinoid
immunomodulating e¡ects [11,12].
Recently, gene modulation studies have generated a great
interest due to the fact that all changes in cell type or state,
whatever the causes, are correlated with changes in gene ex-
pression at both magnitude and timing levels. The ability to
detect and identify the di¡erentially expressed genes in these
processes is a powerful tool for studying any biological event.
In this report, we investigated the e¡ect of a cannabinoid
ligand on gene transcriptional regulation in an attempt to
decipher the function of CB2 in the immune system. Here,
we took the advantage of technological advances to simulta-
neously analyze the expression pattern of hundreds of genes at
a single time. To this end, we used an approach based on
hybridization to large scale arrays containing 588 human
cDNAs ¢xed onto nylon membranes. These hundreds of genes
are organized into groups of functional classes playing key
roles in di¡erent cellular events. As a cellular system, we
used the promyelocytic cell line HL60 that only expresses
the CB2 receptor and lacks CB1 receptor mRNA. Moreover,
since CB2 receptor density is generally low, in order to am-
plify an eventual cannabinoid-induced e¡ect on gene modu-
lation, we arti¢cially overexpressed the receptor of interest by
transfection.
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Fig. 5. E¡ect of CP-55940 on di¡erent K- and L-chemokine family
members. The levels of MCP-1, IL-8, GRO-K and MIP-1K was
measured by ELISA in the culture supernatants of wt-HL60 stimu-
lated for 24 h with 100 nM CP-55940.
Fig. 4. Receptor speci¢city of the CP-induced e¡ect. The CP-in-
duced increase in IL-8 (a) and MCP-1 (b) in wt-HL60 was eval-
uated in the presence (a) or the absence (b) of 100 ng/ml PTX after
a 24 h incubation. The antagonistic e¡ect of SR 144528 on IL-8 (c)
and MCP-1 (d) upregulation was tested in wt HL60 stimulated with
30 nM CP for 24 h. Comparison between the CB1 antagonist SR
141716 (F) and the CB2 antagonist SR 144528 (b) on MCP-1 pro-
duction was similarly done in CB2-HL60 (e). Lower and upper
dashed lines indicate basal and CP induced chemokine production
respectively.
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Using this approach, we demonstrated that nanomolar con-
centrations of CB ligands CP-55940 were able to potently up-
regulate the gene expression of two di¡erent chemokines IL-8
and MCP-1. These enhancements at the genomic level were
correlated with an increase in the production of the corre-
sponding proteins. Furthermore, this observation was ex-
tended to the non-transfected wild-type cells whose IL-8 and
MCP-1 gene expression levels were lower and whose modu-
lation might have been unnoticed without the help of the
corresponding transfected counterparts.
To our knowledge, this is the ¢rst time that a cannabinoid
ligand is shown to induce a modulation of these chemokines.
These e¡ects were speci¢cally mediated by the peripheral can-
nabinoid receptor, since (i) the CB2 speci¢c receptor antago-
nist SR 144528 prevented IL-8 and MCP-1 induction upon
CP-55940 stimulation, (ii) PTX, a Go-Gi protein inhibitor,
abolished the CP-induced e¡ects.
Over 40 chemokines have been identi¢ed to date and sub-
divided into two main families, the K- (or CXC-) chemokines
and the L- (or CC-) chemokines whose IL-8 and MCP-1 are
respective members [24]. We therefore wondered whether
stimulation of IL-8 and MCP-1 was the sign of a general
rise in many chemotactic factor expressions. This issue was
assessed by evaluating the e¡ect of CP-55940 on GRO-K, a
member of the CXC-chemokines as is IL-8, and MIP-1K
which, like MCP-1, belongs to the CC-chemokine family. In
contrast to what was observed with IL-8 and MCP-1, neither
GRO-K nor MIP-1K protein expression was a¡ected, indicat-
ing a possible speci¢c molecular targeting of the CB agonist,
leading to attraction of only restricted leukocyte populations.
Indeed, IL-8 is an important chemotactic factor for neutro-
phils only [25] whereas MCP-1 is mainly involved in the at-
traction of monocytes [26]. These two chemokines have been
detected in a wide variety of in£ammatory diseases such as
asthma, glomerulonephritis, rheumatoid arthritis, atheroscle-
rosis and in£ammatory bowel disease [24]. Their potential role
in these disease processes make an inhibitor of their activities
of great clinical interest.
Therefore, the very surprising observation that CB2 recep-
tors mediated the modulation of these two major in£amma-
tory mediators brought new insights on their function and
might provide a novel target for therapeutic interventions.
Also intriguing was the absence of e¡ect of the putative en-
dogenous ligand anandamide, meaning that perhaps another
endogenous ligand mimicking the e¡ect of the agonist CP-
55940 likely remains to be identi¢ed. In this matter, the avail-
ability of the highly speci¢c CB2 receptor antagonist SR
144528 represents a valuable tool not only to help the char-
acterization of possibly new candidate ligands but also to go
further into the understanding of the role of CB2 receptors in
the modulation of leukocyte recruitment and ¢nally to eval-
uate their commitment in in£ammatory models where these
two chemokines are involved.
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